• Mary-Ann Fitzcharles, Peter A Ste-Marie, Winfried Häuser, Daniel J Clauw, Shahin Jamal, Jacob Karsh, Tara Landry, Sharon Leclercq, Jason J Mcdougall, Yoram Shir, Kam Shojania, and Zach Walsh.
• McGill University Health Centre, Montreal, Quebec, Canada.
• Arthritis Care Res (Hoboken). 2016 May 1; 68 (5): 681-8.

ObjectiveTo assess the efficacy, tolerability, and safety of cannabinoids (phyto- and syntheto-) in the management of rheumatic diseases.MethodsMultiple databases, including Medline, Embase, and CENTRAL, were searched. Randomized controlled trials with outcomes of pain, sleep, quality of life, tolerability (dropouts due to adverse events), and safety (serious adverse events), with comparison of cannabinoids with any type of control, were included. Study methodology quality was evaluated with the Cochrane risk of bias tool.ResultsIn 4 short-term studies comprising 203 patients (58 with rheumatoid arthritis, 71 with fibromyalgia, and 74 with osteoarthritis [OA]), cannabinoids had a statistically significant effect on pain in 2, sleep in 2, and improved quality of life in 1, with the OA study prematurely terminated due to futility. The risk of bias was high for all 3 completed studies. Dizziness, cognitive problems, and drowsiness, as well as nausea, were reported for almost half of the patients. No serious adverse events were reported for cannabinoids during the study duration. No studies of herbal cannabis were identified.ConclusionExtremely small sample sizes, short study duration, heterogeneity of rheumatic conditions and products, and absence of studies of herbal cannabis allow for only limited conclusions for the effects of cannabinoids in rheumatic conditions. Pain relief and effect on sleep may have some potential therapeutic benefit, but with considerable mild to moderate adverse events. There is currently insufficient evidence to recommend cannabinoid treatments for management of rheumatic diseases pending further study.© 2016, American College of Rheumatology.

16 keywords...

hide…